Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer

Mario Spatafora; Vittorio Gebbia; Gianfranco Mancuso; Giovenzio Genestreti; Morena Fasano; Massimo Di Maio; Vittorio Gebbia; Simona Signoriello; Roberto Bianco; Fortunato Ciardiello; Charles Butts; Antonio Rossi; Alberto Ravaioli; Adolfo Favaretto; Floriana Morgillo; Vittorio Fregoni; Natasha B. Leighl; Raffaella Felletti; Yasmin Alam; Mario Spatafora; Saverio Cinieri; Paolo Maione; Rafal Wierzbicki; Ferdinando Riccardi; Alessandro Morabito; Salvatore Siena; Francesco Perrone; Cesare Gridelli; Ming Sound Tsao; Ciro Gallo; Ronald Feld

Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer

Mario Spatafora, Vittorio Gebbia, Gianfranco Mancuso, Giovenzio Genestreti, Morena Fasano, Massimo Di Maio, Vittorio Gebbia, Simona Signoriello, Roberto Bianco, Fortunato Ciardiello, Charles Butts, Antonio Rossi, Alberto Ravaioli, Adolfo Favaretto, Floriana Morgillo, Vittorio Fregoni, Natasha B. Leighl, Raffaella Felletti, Yasmin Alam, Mario SpataforaSaverio Cinieri, Paolo Maione, Rafal Wierzbicki, Ferdinando Riccardi, Alessandro Morabito, Salvatore Siena, Francesco Perrone, Cesare Gridelli, Ming Sound Tsao, Ciro Gallo, Ronald Feld

Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”

Risultato della ricerca: Article › peer review

15 Citazioni (Scopus)

Abstract

The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here.

Lingua originale	English
pagine (da-a)	1830-1844
Numero di pagine	15
Rivista	Journal of Thoracic Oncology
Volume	7
Stato di pubblicazione	Published - 2012

All Science Journal Classification (ASJC) codes

Oncology
Pulmonary and Respiratory Medicine

Accesso al documento

OA Link

Fingerprint Entra nei temi di ricerca di 'Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer'. Insieme formano una fingerprint unica.

Cita questo

Spatafora, M., Gebbia, V., Mancuso, G., Genestreti, G., Fasano, M., Di Maio, M., Gebbia, V., Signoriello, S., Bianco, R., Ciardiello, F., Butts, C., Rossi, A., Ravaioli, A., Favaretto, A., Morgillo, F., Fregoni, V., Leighl, N. B., Felletti, R., Alam, Y., ... Feld, R. (2012). Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. Journal of Thoracic Oncology, 7, 1830-1844.

Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. / Spatafora, Mario ; Gebbia, Vittorio; Mancuso, Gianfranco; Genestreti, Giovenzio; Fasano, Morena; Di Maio, Massimo; Gebbia, Vittorio; Signoriello, Simona; Bianco, Roberto; Ciardiello, Fortunato; Butts, Charles; Rossi, Antonio; Ravaioli, Alberto; Favaretto, Adolfo; Morgillo, Floriana; Fregoni, Vittorio; Leighl, Natasha B.; Felletti, Raffaella; Alam, Yasmin; Spatafora, Mario; Cinieri, Saverio; Maione, Paolo; Wierzbicki, Rafal; Riccardi, Ferdinando; Morabito, Alessandro; Siena, Salvatore; Perrone, Francesco; Gridelli, Cesare; Tsao, Ming Sound; Gallo, Ciro; Feld, Ronald.

In: Journal of Thoracic Oncology, Vol. 7, 2012, pag. 1830-1844.

Risultato della ricerca: Article › peer review

Spatafora, M , Gebbia, V, Mancuso, G, Genestreti, G, Fasano, M, Di Maio, M, Gebbia, V, Signoriello, S, Bianco, R, Ciardiello, F, Butts, C, Rossi, A, Ravaioli, A, Favaretto, A, Morgillo, F, Fregoni, V, Leighl, NB, Felletti, R, Alam, Y, Spatafora, M, Cinieri, S, Maione, P, Wierzbicki, R, Riccardi, F, Morabito, A, Siena, S, Perrone, F, Gridelli, C, Tsao, MS, Gallo, C & Feld, R 2012, 'Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer', Journal of Thoracic Oncology, vol. 7, pagg. 1830-1844.

Spatafora, Mario ; Gebbia, Vittorio ; Mancuso, Gianfranco ; Genestreti, Giovenzio ; Fasano, Morena ; Di Maio, Massimo ; Gebbia, Vittorio ; Signoriello, Simona ; Bianco, Roberto ; Ciardiello, Fortunato ; Butts, Charles ; Rossi, Antonio ; Ravaioli, Alberto ; Favaretto, Adolfo ; Morgillo, Floriana ; Fregoni, Vittorio ; Leighl, Natasha B. ; Felletti, Raffaella ; Alam, Yasmin ; Spatafora, Mario ; Cinieri, Saverio ; Maione, Paolo ; Wierzbicki, Rafal ; Riccardi, Ferdinando ; Morabito, Alessandro ; Siena, Salvatore ; Perrone, Francesco ; Gridelli, Cesare ; Tsao, Ming Sound ; Gallo, Ciro ; Feld, Ronald. / Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. In: Journal of Thoracic Oncology. 2012 ; Vol. 7. pagg. 1830-1844.

@article{903bdcab878b4dbdb738ac827a57bc4f,

title = "Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer",

abstract = "The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here.",

keywords = "Large Cell; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Neoplasm Recurrence, Local; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Male; Female, Questionnaires; Neoplasm Staging; Humans; Salvage Therapy; Prognosis; Quality of Life; Aged; Quinazolines; Research Design; Cisplatin; Deoxycytidine; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Large Cell; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Neoplasm Recurrence, Local; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Male; Female, Questionnaires; Neoplasm Staging; Humans; Salvage Therapy; Prognosis; Quality of Life; Aged; Quinazolines; Research Design; Cisplatin; Deoxycytidine; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma",

author = "Mario Spatafora and Vittorio Gebbia and Gianfranco Mancuso and Giovenzio Genestreti and Morena Fasano and {Di Maio}, Massimo and Vittorio Gebbia and Simona Signoriello and Roberto Bianco and Fortunato Ciardiello and Charles Butts and Antonio Rossi and Alberto Ravaioli and Adolfo Favaretto and Floriana Morgillo and Vittorio Fregoni and Leighl, {Natasha B.} and Raffaella Felletti and Yasmin Alam and Mario Spatafora and Saverio Cinieri and Paolo Maione and Rafal Wierzbicki and Ferdinando Riccardi and Alessandro Morabito and Salvatore Siena and Francesco Perrone and Cesare Gridelli and Tsao, {Ming Sound} and Ciro Gallo and Ronald Feld",

year = "2012",

language = "English",

volume = "7",

pages = "1830--1844",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

}

TY - JOUR

T1 - Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer

AU - Spatafora, Mario

AU - Gebbia, Vittorio

AU - Mancuso, Gianfranco

AU - Genestreti, Giovenzio

AU - Fasano, Morena

AU - Di Maio, Massimo

AU - Gebbia, Vittorio

AU - Signoriello, Simona

AU - Bianco, Roberto

AU - Ciardiello, Fortunato

AU - Butts, Charles

AU - Rossi, Antonio

AU - Ravaioli, Alberto

AU - Favaretto, Adolfo

AU - Morgillo, Floriana

AU - Fregoni, Vittorio

AU - Leighl, Natasha B.

AU - Felletti, Raffaella

AU - Alam, Yasmin

AU - Spatafora, Mario

AU - Cinieri, Saverio

AU - Maione, Paolo

AU - Wierzbicki, Rafal

AU - Riccardi, Ferdinando

AU - Morabito, Alessandro

AU - Siena, Salvatore

AU - Perrone, Francesco

AU - Gridelli, Cesare

AU - Tsao, Ming Sound

AU - Gallo, Ciro

AU - Feld, Ronald

PY - 2012

Y1 - 2012

N2 - The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here.

AB - The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here.

KW - Large Cell; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Neoplasm Recurrence

KW - Local; Adenocarcinoma; Carcinoma

KW - Non-Small-Cell Lung; Male; Female

KW - Questionnaires; Neoplasm Staging; Humans; Salvage Therapy; Prognosis; Quality of Life; Aged; Quinazolines; Research Design; Cisplatin; Deoxycytidine; Lung Neoplasms; Carcinoma

KW - Squamous Cell; Carcinoma

KW - Large Cell; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Neoplasm Recurrence

KW - Local; Adenocarcinoma; Carcinoma

KW - Non-Small-Cell Lung; Male; Female

KW - Questionnaires; Neoplasm Staging; Humans; Salvage Therapy; Prognosis; Quality of Life; Aged; Quinazolines; Research Design; Cisplatin; Deoxycytidine; Lung Neoplasms; Carcinoma

KW - Squamous Cell; Carcinoma

UR - http://hdl.handle.net/10447/80043

M3 - Article

VL - 7

SP - 1830

EP - 1844

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

ER -